



## **Chemed Corporation Board of Directors Authorizes an Additional \$300 Million for Stock Repurchase and Declares Quarterly Dividend of 50 Cents**

November 8, 2024 at 11:43 AM EST

CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2024-- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional \$300 million for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.

The Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company's capital stock, payable on December 6, 2024, to shareholders of record as of November 18, 2024. This is equal to the dividend paid in August 2024. This represents the 214<sup>th</sup> consecutive quarterly dividend paid by Chemed in its 53 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ([www.chemed.com](http://www.chemed.com)) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241107809611/en/): <https://www.businesswire.com/news/home/20241107809611/en/>

Michael D. Witzeman  
(513) 762-6714

Source: Chemed Corporation